|
falls noch jemand von euch dabei ist, heute gehts wieder aufwärts! Sunday June 24, 1:30 am Eastern Time Press Release SOURCE: StressGen Biotechnologies Corp.; Roche Stressgen Biotechnologies and Roche announce global development and marketing collaboration valued up to $204 million U.S. HspE7 is the Lead Novel Fusion Product in Stressgen`s Immunotherapeutic Pipeline for the Treatment of Human Papillomavirus (HPV) VICTORIA, BC, Canada and SAN DIEGO, CA, USA, June 24 /CNW/ - Stressgen Biotechnologies Corporation (TSX:SSB - News) and Roche announced today that they have entered into a Collaboration Agreement for the co-development and global commercialization of Stressgen`s innovative proprietary heat shock protein (Hsp) fusion product candidate. HspE7 is in clinical development for a broad range of human papillomavirus (HPV)-related diseases including cervical and anal dysplasia, precursors to cervical and anal cancer, genital warts and recurrent respiratory papillomatosis (RRP), essentially genital warts of the upper airways, for which the Company has received orphan drug designation. All amounts, unless specified otherwise, are in U.S. dollars. Under the terms of the agreement with Stressgen, Roche will have the worldwide exclusive right to market and sell the HspE7 product and Stressgen will have the right to co-promote the product in the U.S. to certain physician specialties. In addition to an equity investment of $5 million, Roche will pay Stressgen upfront fee and milestone payments, totaling up to $200 million if all development and commercial milestones are achieved, and sales-based payments. "Roche has a long tradition in successfully developing and commercializing anti-viral drugs, alone or in partnership with other companies. Through this agreement, we will strengthen our leadership in this important therapeutic area, and we are looking forward to, together with Stressgen, developing a promising drug which will bring a major treatment advance to patients suffering from HPV," said William M. Burns, Head of Roche`s Pharmaceuticals Division. "We are delighted to partner with Roche, a company that has established a clear leadership position in the diagnosis and treatment of HPV, as well as other serious and chronic viral diseases," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen. "This alliance with Roche validates Stressgen`s achievements to date in the clinic with HspE7, and provides us with an outstanding commercial partner for potential marketing of the first Hsp fusion product for HPV. We expect to build on the success of HspE7, and increase our technology pipeline by developing additional Hsp fusion candidates in the areas of hepatitis B, herpes simplex and HIV viruses." Further financial terms were not disclosed. A joint decision-making governance structure has been established with equal representation from both organizations to oversee and guide the future development of HspE7. The terms of the collaboration agreement are subject to the United States Federal Trade Commission (FTC) approval. HspE7 is in Phase II and Phase III clinical trials for RRP and anal dysplasia. The total market for genital warts, RRP, anal dysplasia and cervical dysplasia represents over one million new patients a year in the U.S. Applying the same proprietary heat shock protein fusion technology that led to the discovery of HspE7, the Company is also advancing a pipeline of novel immunotherapeutics for other serious and chronic viral diseases. About HPV HPV infection is one of the most prevalent sexually transmitted diseases, and it is estimated that there are approximately 5.5 million new cases of genital HPV infections each year in the U.S. alone. HPV infection can also cause recurrent respiratory papillomatosis, a wart infection of the upper airways, and cervical and anal dysplasias, potentially leading to development of cancer. |
|
| aus der Diskussion: | Stressgen gestern + 15,9 % - heute ??? |
| Autor (Datum des Eintrages): | toller (24.06.02 11:30:51) |
| Beitrag: | 36 von 38 (ID:6710980) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |